


Review of Allocation Methodology for Grant Cycle 8: Background, Evaluation Response and Workplan

51st Board Meeting For Board Input

- GF/B51/12
- 22 24 April 2024, Geneva, Switzerland





		•	•	•	•	•	•	•	•							•	•	•	•	•	•	•	٠					
		•	•	•	•	•	•	•							·.			•	•	•	•	•	•	•				
		•	•	•	•	•	•												•	•	•	•	•	•				
		•	•	•	•	•	•														•	•	•	•	•			
ļ		lo		at	io	'n	N	le	th	10	d		Dg	JУ	B	a	ck	g	rc	Ú	nc		•	•	•	•	•	•
		•	•	•	•	•	•															•	•	•	•	•	•	•
		•	•	•	•	•	•	•.						1 .											•	•	•	•
		•	•	•	•	•	•	•																•	•	•	•	•
	•	•	•	•	•	•	•	•	ж. М	×.	•	•		•	•	•	•								•	•	•	•
	•	•	•	•	٠	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•					•	•	•	•
	•	•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	٠
•	•	•	•	٠	٠	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
	THE	GLO	• BAL F	UND										•					•	٠	•	•	•	•	•	•		2
•	•	٠	۲	•	•	•	•	•	•	•										•	•	•	•	•	•	•	•	•

Objectives of Grant Cycle 7 Allocation Methodology


GF/B47/03, 11-12 May 2021

Maximize the impact of available resources by focusing funds on the countries with the highest disease burden and lowest economic capacity, while accounting for key and vulnerable populations disproportionately affected by the three diseases.

In addition, the Grant Cycle 7 (GC7) Allocation Methodology aimed to:

- Support delivery of the "Global Fund Strategy (2023-2028)"
- Provide countries with predictable financing through an approach that is simple and flexible


Key steps of the GC7 Allocation Methodology



What is the Global Disease Split?

- The Global Disease Split (GDS) determines the overall distribution of resources across diseases in the Allocation Methodology.
- Allocations are communicated to countries with an indicative split across eligible diseases, which is *not* the same as the upfront Global Disease Split.
- Countries have the flexibility to request changes to the indicative split when they submit funding requests. This flexibility is key to enable countries to adjust their indicative disease allocations as needed, based on a robust process.

After the upfront split, every step of the allocation methodology is applied within disease to maintain the global disease split



2023-2025 Allocation Methodology

41

What are the technical parameters of the allocation formula?

A		Disease Burden	E	Country Economic Capacity	C	Maximum and Minimum Shares		C External Financing
	HIV TB	Number of people living with HIV [1*TB incidence] + [10*MDR-TB incidence]	X	 Based on GNI per capita Weighted according to a smooth curve, for which 		 Maximum: 10% funding of each disease component; 7.5% 	•	 Projections of other external financing – discounted by
	Malaria	[1*number of malaria cases] + [1*number of malaria deaths] + [0.05*malaria incidence rate] + [0.05*malaria mortality rate] Note: Malaria data from <u>2000-</u> <u>2004</u> , all indicators normalized, <u>cases and deaths adjusted for</u> <u>latest Population-at-Risk</u>		<figure></figure>		 Minimum: USD 500,000 per component for eligible countries 	۲	 50% to account for data quality Can influence component allocations by up to 25%

What is the Qualitative Adjustments (QA) approach?

Stage 1

Refining for epidemiological contexts


Stage 2

One comprehensive adjustment considering key epidemiological, programmatic and other relevant factors to account for effectiveness and need

Adjustment of HIV allocations by accounting for the needs of key populations Upward adjustment to account for key populations in <2% prevalence settings, based on 4 categories

Funds taken from countries with >=2% general prevalence*

*except those with increase in incidence rate, which are excluded from adjustment



¹ Gap to achieving the impact targets set out by the global plans of technical partners in line with Sustainable Development Goal (SDG) 3.

Key contextual factors

- Program performance
- Absorption
- Coverage gaps
- Cost of essential programming
- Economic capacity and other Sustainability, Transition and Co-Financing considerations
- Incidence and mortality trends
- RSSH
- Challenging Operating
 Environments

Supportive Information


Applied through a transparent and accountable process:

- Strategy Committee (SC) approves QA factors and process.
- Secretariat applies the adjustments and reports all changes and rationale to the SC. Changes greater than \$5m and 15% are reported to the Board.

The allocation methodology has been reviewed and refined every cycle to better deliver its objectives

2014	2015	2016	2017	2018	2019	2020	2021	2022	202	23 202	24	2025	2026	2027	2028		
	•	•	•	•	•	•	•	•	C			•	•	•	•		
Gra	ant Cyc	le 4	Gra	int Cyc	le 5	Gra	ant Cyc	le 6		Grant	Сус	le 7	G	ycle 8			
achiev impact line wit burder	develope e greater by fundi h highes and low nic capa	r ng in st vest	the mo impact Strateg probler	nents ma del to d in line v gy, corre ns, and e flexibil	eliver /ith ct	 Malindii indii to a pop Qua adju refin Cat inve to fu sce ens sca 	odates: aria burg cators u account f oulation g alitative ustment alytic estments unding narios to ure suffi le-up in cations	pdated or growth factors s linked o cient	•	y update Global o revised latest ev Scale-up paced re step refi better su different levels Catalytic investme evolved new Stra	disea cons /ider p and educ ined uited t fund c ents to d	sidering nce d tion to be l at ding eliver	tin SI SI SI of of Re co ch int	neline to DG goals upport the the sec the Stra eview late ontext an allenge	ne delivery ond half ategy test nd s to y potential		
ரோ	E GLOBAL	FUND		Delive	er 2017-	2022 S	Strategy	,	Deliver 2023-2028 Strategy								

Context: All three diseases are off-track to meeting the SDGs, particularly TB and malaria



Source: Global Fund Results Report 2023

Context: what has changed since the last allocation review?

- Challenging global funding landscape.
- Debt and unprecedented fiscal pressure, population growth and conflict particularly in lowerincome countries where disease burden is high.
- Increasingly complex malaria response due to climate change and drug/insecticide resistance. New and more effective technologies have been introduced to fight malaria, with further ones in the pipeline.
- Growing and ageing treatment cohort for HIV; erosion of human rights in many countries affecting access to life-saving services.
- Momentum in TB programmatic scale-up, partly due to COVID-19 Response Mechanism (C19RM) investments in lab infrastructure and tests.
- Significant price reductions in key health products for all three diseases.
- Wide-ranging views on a Resilient and Sustainable Systems for Health (RSSH) allocation and expectations on what this would deliver. Also, important sustainability challenges on RSSH funding with C19RM scheduled to end in December 2025.
- Independent evaluation on the allocation methodology, focusing on the Global Disease Split review and the pros/cons of introducing an RSSH allocation.


The Allocation Methodology plays a role in delivering the Strategy and responding to the external environment, but it is only one of many Global Fund levers.

	•	•	•	•	•	•	·	•								•	•	•	•	•	•	•					
••	•	•	•	•	•	•	•	•						·		•	•	•	•	•	•	•	•				
••	•	•	•	•	•	•											•		•	•	•	•	•	•			
••	•	•	•	•	•															•	•	•	•	•			
Se to	_																				•	•	•	•	•	•	•
														U		P I			Ų	•	•	•	•	•	•	•	•
G				∍y	Ģ	ļĠ	Ŏ	•.	ч. 1	ч. С	4	۰.	1.		4						•	•	•	•	•	•	•
••	•	•	•	•	•	•	•.	ж. М	94 1	4	4	•										•	•	•	•	•	•
••	•	•	•	•	•	•		8	ж. М	•	•							•	•				•	•	•	•	•
• •	•	•	•	٠	•	•		•	•	•	•	•	•		•			•			•		•		•	•	•
•••	•	•	•	•	•	•	•	•		•			•	•	•	•		•	•		•		•				•
• •	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•				
• •	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	
• ர тн				•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	• 11	•
• •	•		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	• •	•

Secretariat Management Response

- The Secretariat welcomes the evaluation report and appreciates the independent acknowledgement that many aspects of the Allocation Methodology are working well, as well as the recognition of the constant willingness to review, challenge, and improve the methodology.
- Many of the evaluation's recommendations are to continue current approaches, which in our view signifies confidence in the Allocation Methodology.
- On the Global Disease Split (GDS), the Secretariat agrees with the recommendation to keep an upfront split in the Allocation Methodology. The evaluation also recommends that the GDS be revised in favor of TB to better align with the epidemiological context. However, there is no recommendation on whether the increased share for TB should come from HIV, malaria, or both.
- The evaluation concludes that creating a fourth share for RSSH in the upfront split of the Allocation Methodology is not recommended, which the Secretariat agrees with given the identified risks and challenges.
- Rather, the report recommends that the allocation letters include a percentage of each country's allocation to be dedicated to RSSH, and more directive messaging on RSSH priorities. The Secretariat recognizes the need to strengthen RSSH investments, agrees that both options should be considered to improve the impact of RSSH investments in GC8, and agrees that all available levers should be explored so that the most appropriate measures are taken forward to increase RSSH impact.
- The Secretariat will consider the findings and recommendations as part of the cyclical review of the Allocation Methodology in preparation for Grant Cycle 8 (GC8), including to inform consultations with technical partners, the Strategy Committee and Board.
- The Secretariat appreciates the **strong collaboration with the ELO** on this second review conducted under the new independent evaluation function.
- The Secretariat broadly endorses the key findings and the high-level conclusions from the report and partially agrees with² the recommendations, and endorses the publication of the report, along with the IEP Commentary.

Given the evaluation findings and changing context, we propose to focus the allocation methodology on the following areas




Given significant C19RM investments in RSSH (and TB to some extent), should the allocations account for this, and if so, how?

Global Disease Split: Proposed approach for the review

5

on the needs for each disease



Board

14

RSSH: Considering all levers to increase the impact of GF investments

An RSSH allocation is:

- An amount of GF resources committed to all or a selection of eligible countries;
- Applied to meet the aims of the allocation methodology and driven by clear principles;
- For direct RSSH only, because contributory RSSH is defined as disease investments that strengthen RSSH;
- Driven by the equivalent of a burden metric which is rigorous, relevant to our mission, up-to-date and available in all countries;
- Arrived at formulaically and adjusted in QA, or determined in QA, aligned to SC approvals; and
- An RSSH amount communicated to countries in the allocation letters.

Without an RSSH allocation, the GF can use other levers to increase impact, including:

Allocation Letter	 Previous and/or recommended RSSH funding levels Recommended RSSH priorities Recommended implementation arrangements Required co-financing Required integrated approach to funding requests Differentiated approach with more prescriptive messaging for RSSH priority countries Grant Cycle 7 Allocation Letters For RSSH priority countries, the GF "expects the country to maintain or increase its RSSH and pandemic preparedness (PP) investments and would suggest a focus on the following priority areas" All other countries, the GF " recommends that the level of country investment in
ССМ	RSSH be maintained where appropriate and increased where possible" Strengthen CCM's for better RSSH oversight, improve implementation arrangements to better deliver, and to ensure technical assistance (TA) arrangements are fit-for-purpose
Grant Reporting	Strengthen tracking and accountability of investments throughout grant lifecycle


July SC25: Discussion on options to increase the impact of RSSH investments – for SC input

ら THE GLOBAL FUND

Next step for 2024

High-level decision-making timeline

Allocation Methodology GC8



Questions for the Board

- Does the Board have questions or comments on the allocation methodology evaluation?
- Does the Board agree with the proposed focus of review for the GC8 allocation methodology?
- Does the Board agree with the proposed approach to the Global Disease Split review? What additional factors should we consider?
- Does the Board agree to explore all levers to expand RSSH impact outside of an allocation?
- Does the Board agree with the decision-making timeline?